II. Indications
- Narcolepsy
- Non-FDA approved use
III. Contraindications (relative)
- Coronary Artery Disease
- Hypertension
- Other cardiovascular disease
IV. Mechanism
- Stimulant
V. Dosing: Adults
- ADHD: 100-300 mg PO qd (Not FDA approved)
- Narcolepsy: 200 mg qAM
VI. Dosing: Children Age >5 years
- ADHD: 50-100 mg PO qd (Not FDA approved)
VII. Efficacy: Narcolepsy
- May be slightly less effective then agents above
- Less addictive potential then agents above
- (1999) Med Lett Drugs Ther 41(1049):30-2 [PubMed]
VIII. Efficacy: ADHD
- Only small studies to show effectiveness and safety
- References
IX. Adverse Effects
- Headache
- Nervousness
- Dizziness
- Depressed mood
- Anxiety
- Cataplexy
- Insomnia
- Diarrhea
- Nausea
- Xerostomia
- Anorexia
- Paresthesias
- Pharyngitis or Rhinitis
X. References
- (2003) Lexi-Comp Drug Database for Pocket PC (7/9/03)
Images: Related links to external sites (from Bing)
Related Studies
modafinil (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
MODAFINIL 100 MG TABLET | Generic | $0.30 each |
MODAFINIL 200 MG TABLET | Generic | $0.60 each |
provigil (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
PROVIGIL 200 MG TABLET | Generic | $0.60 each |
Ontology: modafinil (C0066677)
Definition (NCI) | A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine. This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. (NCI04) |
Definition (NCI_NCI-GLOSS) | A drug that is being studied as a treatment for fatigue in patients with cancer. It belongs to the family of drugs called stimulants. |
Definition (PDQ) | A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine. This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26661" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C048833 |
SnomedCT | 116082007, 387004007 |
LNC | LP66956-1, MTHU028053 |
English | benzhydrylsulfinylacetamide, modafinil, modafinil (medication), MODAFINIL, modafinil [Chemical/Ingredient], 2-((diphenylmethyl)sulfinyl)acetamide, Modafinil, Modafinil (product), Modafinil (substance) |
Spanish | modafinilo, modafinilo (producto), modafinil, modafinilo (sustancia), modafinil (producto), modafinil (sustancia) |
Ontology: Provigil (C0722882)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C048833 |
English | Provigil, modafinil (Provigil), provigil, Cephalon brand of modafinil |